Cagrilintide
$144.00
an investigational, long-acting amylin analog developed by Novo Nordisk for chronic weight management and type 2 diabetes, primarily studied in combination with semaglutide (known as CagriSema). It works differently from GLP-1 receptor agonists by mimicking the natural hormone amylin to suppress appetite, delay gastric emptying, and promote satiety.
99%+
PURITY
GUARANTEED
7
QUALITY
CHECKS
100%
U.S.
SOURCED
For research use only. Not for human consumption. Products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm that you are 21+ and conducting legitimate laboratory research.
Product Information
Benefits Cagrilintide
- Weight Loss
- Appetite Control
- Improved Satiety Signaling
- Fat Loss
Potential Side Effects
- Nausea
- Diarrhea or loose stool
- Abdominal Pain or Cramps
Dosage
Sub-Q Injection: Appetite Modulation Intro
Dosage: 0.3–0.6 mg per dose
Frequency: Once Weekly
Timing: Same day each week
Cycle: 8–12 weeks
